Smith Hanley Consulting Group LLC, Durham, NC, USA.
Am J Cardiol. 2011 Mar 15;107(6):891-7. doi: 10.1016/j.amjcard.2010.11.008. Epub 2011 Jan 19.
A growing amount of evidence has supported an association between elevated triglyceride levels and cardiovascular disease. However, little information regarding co-morbidities, levels of other cholesterol types, or medication use among adults with severe hypertriglyceridemia (SHTG; (500 to 2,000 mg/dl) is available. We examined the data from 5,680 subjects, ≥ 20 years old, who had participated in the National Health and Nutrition Examination Survey from 2001 and 2006, to evaluate the epidemiology of adults with SHTG. Approximately 1.7% of the sample had SHTG, equating to roughly 3.4 million Americans. The participants with SHTG tended to be men (75.3%), non-Hispanic whites (70.1%), and aged 40 to 59 years (58.5%). More than 14% of those with SHTG reported having diabetes mellitus, and 31.3% reported having hypertension. Only 14% of the subjects with SHTG reported using statins, and 4.0% reported using fibrates. The factors significantly associated with having SHTG included high-density lipoprotein <40 mg/dl (odds ratio [OR) 11.45, 95% confidence interval [CI] 6.28 to 20.86), non-high-density lipoprotein 160 to 189 mg/dl (OR 9.74, 95% CI 1.68 to 56.40) or non-high-density lipoprotein ≥ 190 mg/dl (OR 24.99, 95% CI 3.90 to 160.31), diabetes mellitus (OR 3.04, 95% CI 1.45 to 6.37), and chronic renal disease (OR 7.32, 95% CI 1.45 to 36.94). In conclusion, SHTG is rare among adults in the United States and the use of pharmacologic intervention is low among those with SHTG.
越来越多的证据表明，甘油三酯水平升高与心血管疾病之间存在关联。然而，对于严重高甘油三酯血症（SHTG；（500 至 2000mg/dl）患者的合并症、其他胆固醇类型的水平或药物使用情况，相关信息较少。我们对 2001 年至 2006 年期间参加国家健康和营养检查调查的 5680 名年龄在 20 岁及以上的受试者的数据进行了检查，以评估 SHTG 成年患者的流行病学情况。大约 1.7%的样本患有 SHTG，相当于约 340 万美国人。患有 SHTG 的患者多为男性（75.3%）、非西班牙裔白人（70.1%）和 40 至 59 岁（58.5%）。超过 14%的 SHTG 患者报告患有糖尿病，31.3%报告患有高血压。只有 14%的 SHTG 患者报告使用他汀类药物，4.0%报告使用贝特类药物。与患有 SHTG 显著相关的因素包括高密度脂蛋白<40mg/dl（比值比[OR]11.45，95%置信区间[CI]6.28 至 20.86）、非高密度脂蛋白 160 至 189mg/dl（OR 9.74，95% CI 1.68 至 56.40）或非高密度脂蛋白≥190mg/dl（OR 24.99，95% CI 3.90 至 160.31）、糖尿病（OR 3.04，95% CI 1.45 至 6.37）和慢性肾脏疾病（OR 7.32，95% CI 1.45 至 36.94）。总之，在美国成年人中，SHTG 较为罕见，且 SHTG 患者使用药物干预的情况也较低。
